GlassScriptPhysician profile
Rachel E Pratt
NPI 1205490539
$2,378.01
in general payments reported to CMS, 2019-2025
22 companies · $573 in 2025
The $573 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $205 · 2023: $571 · 2024: $1,029 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $676.51 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $430.77 | 2022-2025 | Azstarys |
| Neos Therapeutics, LP | $170.07 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Cranial Technologies, INC | $120.87 | 2022-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $99.06 | 2023-2024 | Flumist Quadrivalent |
| Merck Sharp & Dohme LLC | $98.67 | 2022-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $95.59 | 2022-2024 | |
| Kaleo, INC. | $83.54 | 2023-2024 | Auvi-Q |
| Collegium Pharmaceutical, INC. | $77.02 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $75.98 | 2023-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $58.38 | 2024-2025 | Bexsero |
| Seqirus USA INC | $57.07 | 2024-2025 | Flucelvax |
| Alk-Abello, INC | $51.90 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $50.77 | 2024 | |
| Pfizer INC. | $49.36 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $40.32 | 2023-2025 | Dyanavel Xr |
| Kowa Pharmaceuticals America, INC. | $31.87 | 2024-2025 | Zoryve |
| Vertical Pharmaceuticals, LLC | $28.30 | 2025 | Relexxii |
| Takeda Pharmaceuticals U.S.A., INC. | $25.25 | 2025 | Elaprase |
| Lnhc, INC | $21.50 | 2025 | Zelsuvmi |
| Biomarin Pharmaceutical INC. | $19.50 | 2025 | Voxzogo 1.2mg |
| Exeltis, USA INC. | $15.71 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.